AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03841188 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nutritional orientation
Description: Nutritional orientation with emphasis in rich calcium food
Study NCT02039362 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir DF
Description: Tenofovir DF will be started at week 28 of pregnancy and stopped or not, according to the physician's decision, at week 12 after birth
Study NCT01983761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative)
Study NCT01983761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine, Melphalan, ATG (Reduced Intensity)
Study NCT03968718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Systematic ePROMs Assessment
Description: Depending on the care setting, eligible patients will be asked to fill in one of the following e-PROMs assessment:~Edmonton symptom assessment scale (ESAS-r) (outpatients)~Distress Thermometer (inpatients)~An ad hoc questionnaire adapted from the Bench-Can and EURACAN projects plus the institutional customer satisfaction survey (patients followed by multidisciplinary teams)
Study NCT01374750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus
Study NCT01374750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: m-TOR inhibitor free
Description: calcineurin inhibitors
Study NCT03603314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SENS-401
Description: 29 mg dose group: tablets of 14.5 mg, oral route, by mouth, twice a day, during 4 weeks
Study NCT03603314 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo, oral route, by mouth, twice a day, during 4 weeks
Study NCT03603314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SENS-401
Description: 43.5 mg dose groupe: tablets of 14.5 mg, oral route, by mouth, twice a day, during 4 weeks
Study NCT03151057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib 100 MG
Description: 100mg BID beginning on day 90 (+/- 10days) and continuing until day 270 post transplant.
Study NCT03151057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo
Study NCT03518281 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole Cell Euglena containing Beta Glucan
Description: Whole Cell Euglena containing >50% Beta Glucan
Study NCT03518281 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: microcrystalline cellulose, hypromellose, titanium dioxide, water
Study NCT01316445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nasal Midazolam
Description: Intranasal and buccal administration of the standard IV formulation of midazolam (5mg/mL), administered via a metered dose sprayer at 0.1mL/spray (i.e. 0.5mg/spray). Administration will be via three sprays in each nostril (for nasal) or three sprays between the cheek and the gum per side (for buccal).
Study NCT00109473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: growth hormone
Description: Nutropin AQ 0.075mg/kg/day subcutaneously daily
Study NCT03368755 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Exercise Testing
Description: Pimax, Pemax, airway pressure at 100 msec after occlusion (P0.1), and Ti and Ttot will be measured by the Micro 5000 device (Medisoft, Sorinnes, Belgium). TTImus will be calculated as (Pimean / Pimax) x (Ti / Ttot), where Pimean is the mean airway pressure resulting from the formula Pimean = 5 x P0.1 x Ti9. RM function will be determined a) prior to CPET, b) during CPET when the anaerobic threshold (AT) will be reached, and c) after CPET, when heart rate (HR) and oxygen consumption will be normalized.
Study NCT01717053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: 1000 mg orally once a day for 6 months.
Study NCT03368755 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary Exercise Testing
Description: Pimax, Pemax, airway pressure at 100 msec after occlusion (P0.1), and Ti and Ttot will be measured by the Micro 5000 device (Medisoft, Sorinnes, Belgium). TTImus will be calculated as (Pimean / Pimax) x (Ti / Ttot), where Pimean is the mean airway pressure resulting from the formula Pimean = 5 x P0.1 x Ti9. RM function will be determined a) prior to CPET, b) during CPET when the anaerobic threshold (AT) will be reached, and c) after CPET, when heart rate (HR) and oxygen consumption will be normalized.
Study NCT03368755 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Respiratory Muscle Strength and Endurance
Description: CPET will be performed by the Ultima CPX system (Medgraphics, St. Paul, USA), using a cycle ergometer and according to a standardized protocol. The following parameters will be recorded: total work in Watts, maximum HR, maximum oxygen consumption (VO2max), AT indices (work, HR, VO2 ) and duration of recovery.
Study NCT03368755 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory Muscle Strength and Endurance
Description: CPET will be performed by the Ultima CPX system (Medgraphics, St. Paul, USA), using a cycle ergometer and according to a standardized protocol. The following parameters will be recorded: total work in Watts, maximum HR, maximum oxygen consumption (VO2max), AT indices (work, HR, VO2 ) and duration of recovery.
Study NCT04400123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib malate
Description: TR group:~The first period，the subjects will be administrated with Famitinib malate in new formulation, then conduct blood collection within 192h; 14 days washout；The second period，the subjects will be administrated with Famitinib malate in old formulation, then conduct blood collection within 192h.~RT group:~The first period，the subjects will be administrated with Famitinib malate in old formulation, then conduct blood collection within 192h; 14 days washout；The second period，the subjects will be administrated with Famitinib malate in new formulation, then conduct blood collection within 192h.
Study NCT01717053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation
Description: LHRH analog (at discretion of treating physician) will be administered over 6 months (for example, leuprolide acetate 22.5mg IM or goserelin acetate 10.8mg SC given every 3 months for 2 doses).
Study NCT01717053 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Daily (Monday-Friday) for 8 weeks, final dose of 75-80 Gy
Study NCT01717053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg tablet once daily for 6 months.
Study NCT01460511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E004 (Epinephrine Inhalation Aerosol) HFA-MDI
Description: E004 (Epinephrine Inhalation Aerosol) HFA-MDI, 125 mcg/inhalation, 2 inhalations QID
Study NCT01460511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-HFA
Description: Placebo-HFA, 0 mcg/inhalation, 2 inhalations QID
Study NCT01464281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa 2a
Description: Group 1 : 48-week standard treatment by Peginterferon alfa 2a 180µg/week Group 2 : 96-week prolonged treatment by Peginterferon alfa 2a 180µg/week.
Study NCT01464281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa 2a
Description: Group 1 : 48-week standard treatment by Peginterferon alfa 2a 180µg/week Group 2 : 96-week prolonged treatment by Peginterferon alfa 2a 180µg/week.
Study NCT03876392 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Compare bone marrow biopsy with magnetic resonance imaging to detect bone marrow metastases
Study NCT04129151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Oral, per protocol pre determined dosage, once a day for 21 days
Study NCT04129151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganitumab
Description: -Intravenous, per protocol predetermined dosage, twice per cycle
Study NCT03517345 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: Prebiotic (Inulin+Oligofructose) consumed as 10 g/d in yogurt (200 g/d)
Study NCT03517345 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: The only yogurt consumed as 200 g/d without prebiotic.
Study NCT03034551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive, Mobile Phone App, and Cellular Scale
Description: Subjects will be provided a cellular-connected digital scale and will be offered $150 to use the app each day to log one daily self-weighing and one medication check-in. Medication check-ins consist of uploading daily photos of pills at the time of self-administration through the Wellth app. If a 2 lb or greater daily increase in weight, or a 5 lb weekly increase in weight is detected in any patient, a UMCPP physician or nurse will be alerted via automatic email and text. A physician or a nurse will then call the patient to assess the patient's symptoms. If there are increasing heart failure symptoms, the physician or nurse will suggest the patient see their doctor within the next 48 hours and will notify the patient's primary care physician and cardiologist.
Study NCT01788410 — intervention group
Intervention type: PROCEDURE
Intervention: Cryoablation under image guidance
Description: Observing efficacy of cryoablation to nerves and facet joints for the treatment of radicular pain and pain resulting from facet joint disease.
Study NCT01788410 — intervention group
Intervention type: DEVICE
Intervention: MRI Seednet Cryotherapy System (Galil Medical)
Description: Observing efficacy of cryoablation to nerves and facet joints for the treatment of radicular pain and pain resulting from facet joint disease.
Study NCT02303392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO
Study NCT02303392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT02303392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02303392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03708354 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo softgel
Description: One 430 mg olive oil softgel daily for 24 weeks. Each placebo softgel of 430 mg olive oil will contain no tocotrienol or tocopherols at detectable levels.
Study NCT03708354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DeltaGold® Tocotrienol 70%
Description: Each TT softgel (DeltaGold® Tocotrienol 70%) contains 430 mg TT (90% δ-TT+10% γ-TT) with a 70% purity, representing 300 mg TT.
Study NCT04195542 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: questionnaire assessing knowledge of the need to take vitamin B9 supplementation in women in the periconceptional period and the reasons why this supplementation is carried out or not
Study NCT01595022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Flexi ring FR01
Description: Intrauterine device, inserted once for 3 months
Study NCT01595022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Flexi ring FR20
Description: Intrauterine device, inserted once for 3 months
Study NCT01595022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Ultra low dose levonorgestrel contraceptive system (LCS)
Description: Intrauterine device, inserted once for 3 months
Study NCT03032302 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Swisse Womens 50+ Ultivite Multivitamin
Description: Single tablet taken once daily
Study NCT00109473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cortecosteroid
Description: As prescribed by the referring gastroenterologist
Study NCT02495727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step-reduction
Description: Participants will reduce the number of steps they take each day to less than 1, 500 for two weeks, using a pedometer to monitor their daily step count.
Study NCT03032302 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Holland and Barrett Triple Strength Omega-3 Fish Oil
Description: Single capsule taken once daily
Study NCT00086268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Study NCT03203863 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: anthropometric measures of fatness
Description: The aim of this study was to determine the discrimination capacity for cardiovascular risk factors of BMI, fat mass (FM), waist circumference (WC), and waist to height ratio (WHtR) in a population of Chilean children from Puente Alto County. Additionally, new cutoff points were established and compared with those described by other authors
Study NCT00086268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Study NCT00086268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT03522623 — intervention group
Intervention type: OTHER
Intervention: Non-interventional study
Description: Non-interventional study
Study NCT00502411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 17.5 mg/m\^2 IV bolus infusion, followed by continuous IV infusion on days 1-4.
Study NCT00502411 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation treatments 5 days a week for 6 - 6 1/2 weeks. 60 Gy in 6 weeks (negative resection margin) to 66 Gy in 6.5 weeks (positive resection margin).
Study NCT02594995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBP
Study NCT02156271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ramelteon
Study NCT02156271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02069275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate mobilization
Description: Patients are mobilized immediate after coronary angiography and percutaneous coronary intervention via femoral access and closed with Angio-seal closing device. Heparin reverted with Protaminsulphate
Study NCT02069275 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Two hours bedrest
Description: Patients is following the usual regimen, two hours bedrest after coronary angiography and percutaneous coronary intervention via femoral access and closed with Angio-seal closing device before mobilization. Heparin is reverted with Protaminsulphate
Study NCT04209985 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coaching
Description: Brief telephonic intervention consisting of up to five phone calls from a health coach
Study NCT01075308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDAC inhibitor SB939
Description: SB939 given orally every other day 3 times a week (i.e. Monday /Wednesday /Friday, or Tuesday /Thursday / Saturday) for 3 consecutive weeks followed by one week off-dosing. A treatment cycle is 4 weeks (28 days).
Study NCT01774656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacological Treatment
Description: The pharmacological treatment intended to enhance reverse remodeling includes 4 drugs initiated immediately after weaning of inotropic support once achieving adequate end-organ recovery and titrated (against symptoms, potassium, and renal function) to the following maximum doses: lisinopril 40 mg daily; carvedilol 25 mg 3 times daily; spironolactone 25 mg daily; digoxin 125g daily, and losartan 150 mg daily.
Study NCT01862692 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baby-Net
Description: Parents randomized to the intervention condition will receive a computerized adaptation of the empirically supported PALS parenting program as well as a laptop and wireless Internet connection. In this study, we adapted original 10-session PALS program for computer administration and included a session on reading (Read to Me, Inc.; http://www.readtomeprogram.org/index.html), developed to be incorporated within the PALS program. Each session includes the following: (a) a presentation of concepts, behaviors, and examples, (b) check-in questions recorded to the data base for review by both parent and coach, (c) the creation of a 5 minute computer-collected video of mother-infant interactions for later review by coach and parent, (d) a summary of topics, (e) daily activities (homework), (f) feedback about the program recorded to the database and (g) a weekly telephone coach call to review mother-infant computer-administered video and session topics and skills.
Study NCT01862692 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Developmental Awareness Skills
Description: Mothers in this condition will receive weekly phone contact with a coach as well as a laptop and wireless Internet connection. The laptop will contain a computer-based infant intervention program that is structurally similar to the Infant Program in terms of components (e.g., information pages, mother-infant video recording pages; coach contact pages), however weekly information will focus on their infants' development, with no direct maternal skills instruction. Mothers in this condition will receive the same number of contacts with the computer and coach as mothers in the InfantNet condition and will participate in weekly phone calls with a coach. During phone calls, parents will co-view weekly mother-infant video with their coach, with mothers having been instructed to play with their infant (with no prescribed tasks to perform) and the discussion will focus on general infant development.
Study NCT04271618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TheraTogs Orthotic Undergarment
Description: Strapping undergarment made from a lightweight, breathable fabric that is velcro sensitive. It consists of sleeveless vest (tank-Top), two shorts (Hipster) each with two thigh cuffs and limb cuffs
Study NCT04271618 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TheraTogs Orthotic Undergarment
Description: Strapping undergarment made from a lightweight, breathable fabric that is velcro sensitive. It consists of sleeveless vest (tank-Top), two shorts (Hipster) each with two thigh cuffs and limb cuffs
Study NCT00906737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle-bot
Description: The Ankle-bot is a piece of robotic therapy equipment for the ankle. In this study, it will be used to guide and assist the subject into ankle flexion, extension, inversion and eversion.
Study NCT00906737 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional focused ankle therapy
Description: Conventional focused ankle therapy will be performed by a physical therapist.
Study NCT00949494 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Synvisc
Description: intra-articular, 3 weekly injections
Study NCT00949494 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synvisc
Description: intra-articular, 3 weekly injections
Study NCT02880956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-8E12
Description: ABBV-8E12 solution for IV infusion
Study NCT02880956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for ABBV-8E12
Description: placebo solution for intravenous (IV) infusion
Study NCT00620932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Patients will be randomly assigned to groups and will either be given an exercise program individually tailored to them for them to participate in for 6 months or else be wait-listed for 6 months and remain on whatever exercise regimen they were already on.
Study NCT01661842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional plus UC-MSC treatment
Description: Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks.
Study NCT02495727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-training
Description: Participants will attend 10 strength training exercise sessions over a four week period prior to the step-reduction intervention. These exercise sessions will be focused on lower limb strength, fully supervised and will be progressive.
Study NCT02495727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise snacking
Description: Participants will perform three bouts of five minutes of exercise each day during the two week step-reduction intervention. These will consist of five discrete exercises, each performed continuously for one minute, with one minute of rest between each exercise. These exercises will be non-supervised, and require no specialist equipment.
Study NCT01661842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional plus placebo treatment
Description: Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks
Study NCT02906982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gum health formulation in intra-oral device
Description: The intervention is a gum health formulation for periodontal disease care and teeth whitening to be used within an accelerating intra-oral device.
Study NCT02906982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gum health formulation on toothbrush
Description: The intervention is a gum health formulation for periodontal care and teeth whitening to be used on a toothbrush alongside standard toothpaste.